(Q42999160)

12 November 2017

title

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response (English)

1 reference

12 November 2017

0 references

1 reference

Diego Rincón

6

0 references

author name string

Conrado M Fernández-Rodríguez

1

1 reference

12 November 2017

Sonia Alonso

2

1 reference

12 November 2017

Stella M Martinez

3

1 reference

12 November 2017

Xavier Forns

4

1 reference

12 November 2017

Jose M Sanchez-Tapias

5

1 reference

12 November 2017

Gil Rodriguez-Caravaca

7

1 reference

12 November 2017

Rafael Bárcena

8

1 reference

12 November 2017

Miguel A Serra

9

1 reference

12 November 2017

Manuel Romero-Gómez

10

1 reference

12 November 2017

Inmaculada Fernandez

11

1 reference

12 November 2017

Javier Garcia-Samaniego

12

1 reference

12 November 2017

Javier Fuente

13

1 reference

12 November 2017

Ricard Solá

14

1 reference

12 November 2017

Ricardo Moreno-Otero

15

1 reference

12 November 2017

Ramón Planas

16

1 reference

12 November 2017

Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR)

17

1 reference

12 November 2017

language of work or name

English

0 references

publication date

10 August 2010

1 reference

The American Journal of Gastroenterology

12 November 2017

published in

1 reference

12 November 2017

volume

105

1 reference

12 November 2017

issue

10

1 reference

12 November 2017

page(s)

2164-72; quiz 2173

1 reference

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Prediction of variceal hemorrhage by esophageal endoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.294

21 January 2018

Identifiers

DOI

10.1038/AJG.2010.294

1 reference

12 November 2017

1 reference